Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Lumiera Health Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

Have Insiders Been Buying Lumiera Health Inc. (CVE:NHP) Shares?

Feb 16

CEO

Lumiera Health CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marie Belanger	Independent Director	4.1yrs	Veri yok	0.088% CA$ 750.0
Louis Doyle	Independent Director	2.9yrs	Veri yok	0.25% CA$ 2.1k
André Rancourt	Director	less than a year	CA$11.67k	10.09% CA$ 85.8k
Jacqueline Khayat	Independent Director	2.7yrs	CA$5.97k	0.082% CA$ 701.0
Shawn Moniz	Independent Director	less than a year	Veri yok	Veri yok
Kevin Cole	Independent Chairman	4.1yrs	Veri yok	0.33% CA$ 2.8k

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: NHP.H 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Lumiera Health Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lumiera Health Inc., Annual General Meeting, Nov 14, 2023

Lumiera Health Inc. Announces Board Resignations

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Lumiera Health Appoints Jacqueline Khayat to Board of Directors

Recent updates

Lumiera Health's Listing to Transfer to NEX from Tier 2 Effective at the Opening on April 19, 2024

Lumiera Health Inc., Annual General Meeting, Nov 14, 2023

Lumiera Health Inc. Announces Board Resignations

Less than half of directors are independent

Lumiera Health Inc. announced that it expects to receive CAD 0.6 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2021)

Lumiera Health Inc. to Report Q3, 2022 Results on Oct 28, 2022

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.009 profit in 2Q 2021)

Lumiera Health Inc. to Report Q2, 2022 Results on Jul 29, 2022

Lumiera Health Inc. Files New NPN Application with Health Canada to Extend Awaye Pain Relief Product Line

Less than half of directors are independent

Lumiera Health Appoints Jacqueline Khayat to Board of Directors

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Lumiera Health Begins Sales of Awaye Pain Relief Cream on Amazon Marketplace

Lumiera Health Inc. announced that it expects to receive CAD 0.9 million in funding

Second quarter 2021 earnings released: EPS CA$0.009 (vs CA$0.006 loss in 2Q 2020)

Lumiera Health Inc. announced that it expects to receive CAD 1.3 million in funding

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.005 loss in 1Q 2020)

Lumiera Health Inc. Announces Executive Changes

Full year 2020 earnings released: CA$0.029 loss per share (vs CA$0.027 loss in FY 2019)

Have Insiders Been Buying Lumiera Health Inc. (CVE:NHP) Shares?

Lumiera Health Inc. Announces Management Changes

Lumiera Health Inc. Announces the Commercial Launch of Bazzzics a Natural, Over-The-Counter Product Lines, Targeting Sleep Disorders and Anxiety

Insider recently bought CA$295k worth of stock

Third quarter earnings released

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Mondias Natural Products Inc. announced that it expects to receive CAD 1 million in funding

Mondias Natural Products Inc Announces Executive Changes

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi